Ribomic Inc.
Supplementary Explanation Regarding the Items for the 23rd Annual General Meeting of Shareholders
Supplementary explanation for proposed change in authorized shares to prepare for funding needs. The objective is to secure flexibility for future fundraising; no immediate execution is assumed at present, while acknowledging dilution risk and ensuring mobility.
Key Figures
- Raise of authorized shares level: Unknown
- Possibility of share issuance through exercise of stock options: Unknown
- Current amount of funds to be raised: Unknown
AI要約
Overview of Capital Policy
This proposal is to secure capital policy flexibility by establishing the authorized shares cap as a framework to anticipate future funding needs accompanying business growth. It does not decide on a specific fundraising at this time and aims to retain options to meet future funding demands. Note that, considering the exercise of already allotted stock options, the current cap may lack flexibility, hence the setup increases the ceiling to a comfortable level. Raising the authorized shares is a matter requiring a special resolution, and actual implementation will depend on circumstances.
Future Operating Policy and Considerations
The proposal is not dependent on any particular fundraising method and priority is given to non-dilutive funds such as external collaboration, partnerships, and joint research agreements. It is a foundational measure to broaden capital policy options, and decisions will be made comprehensively from the perspectives of future business growth and enterprise value. At present, there are no plans to issue new stock options or new shares, and careful consideration will be given to minimize shareholder value dilution risk.
Ribomic Corporation
Company overview · Stock price · Financial data · All IR
